Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
Emergent BioSolutions (NYSE: EBS) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025 at 5:00 PM ET. The call will be available live via webcast and by telephone with advance registration; registered telephone participants receive a confirmation email with dial-in numbers, a unique passcode, and registrant ID. A replay will be accessible on the company’s Investors page.
Emergent BioSolutions (NYSE: EBS) pubblicherà risultati finanziari del terzo trimestre 2025 e ospiterà una conferenza telefonica mercoledì 29 ottobre 2025 alle 17:00 ET. La chiamata sarà disponibile in diretta via webcast e per telefono previa registrazione; i partecipanti telefonici registrati riceveranno un'email di conferma con i numeri da comporre, un passcode univoco e l'ID del registrante. La riproduzione sarà accessibile nella pagina Investitori dell'azienda.
Emergent BioSolutions (NYSE: EBS) publicará los resultados financieros del tercer trimestre 2025 y organizará una conferencia telefónica el miércoles 29 de octubre de 2025 a las 5:00 p.m. ET. La llamada estará disponible en vivo por webcast y por teléfono con registro previo; los participantes telefónicos registrados recibirán un correo de confirmación con números de marcado, un código de acceso único y un ID de registrante. Una repetición estará disponible en la página de Inversores de la empresa.
Emergent BioSolutions (NYSE: EBS)는 2025년 제3분기 재무 실적를 발표하고 2025년 10월 29일 수요일 동부 표준시 오후 5시에 컨퍼런스 콜을 주최합니다. 전화로도 사전 등록을 통해 라이브로 들을 수 있으며, 등록된 전화 참가자는 다이얼 인 번호, 고유 패스코드 및 등록자 ID가 포함된 확인 이메일을 받습니다. 재생은 회사의 투자자 페이지에서 확인할 수 있습니다.
Emergent BioSolutions (NYSE: EBS) publiera les résultats financiers du troisième trimestre 2025 et organisera une conférence téléphonique le mercredi 29 octobre 2025 à 17h00 HE. L’appel sera disponible en direct par webcast et par téléphone sur inscription préalable; les participants téléphoniques inscrits recevront un e-mail de confirmation avec les numéros d’accès, un code d’accès unique et l’identifiant de l’inscrit. Une rediffusion sera accessible sur la page Investisseurs de l’entreprise.
Emergent BioSolutions (NYSE: EBS) wird die Finanzergebnisse des dritten Quartals 2025 melden und am Mittwoch, dem 29. Oktober 2025 um 17:00 Uhr ET eine Telefonkonferenz abhalten. Der Anruf wird live per Webcast und telefonisch mit vorheriger Registrierung verfügbar sein; registrierte Telefonteilnehmer erhalten eine Bestätigungs-E-Mail mit Einwahldaten, einem eindeutigen Passcode und der Registrierungs-ID. Eine Wiederholung wird auf der Investorenseite des Unternehmens zugänglich sein.
Emergent BioSolutions (NYSE: EBS) ستعلن عن نتائج الربع الثالث من عام 2025 وستعقد مكالمة مؤتمر عبر الهاتف يوم الأربعاء 29 أكتوبر 2025 الساعة 5:00 مساءً بتوقيت شرق الولايات المتحدة. ستكون المكالمة متاحة مباشرة عبر الويب والهاتف مع التسجيل المسبق؛ سيتلقى المشاركون الهاتفيون المسجلون رسالة بريد إلكتروني تحتوي على أرقام الاتصال ورمز وصول فريد ومعرّف المسجِّل. يمكن الرجوع إلى البث على صفحة المستثمرين بالشركة.
Emergent BioSolutions (NYSE: EBS) 将公布2025 年第三季度财务业绩，并于2025 年 10 月 29 日星期三美国东部时间下午 5:00召开电话会议。通话将通过网络直播和电话提供，需事先注册；注册的电话参与者将收到包含拨打号码、唯一访问码和登记人 ID 的确认邮件。回放可在公司投资者页面获取。
- None.
- None.
GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025.
Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) report Q3 2025 results and hold the conference call?
How can investors listen to the Emergent BioSolutions (EBS) Q3 2025 earnings call?
What do telephone participants need to join the EBS October 29, 2025 call?
Where can I find the replay of Emergent BioSolutions (EBS) Q3 2025 conference call?
Is registration required to participate by phone in the EBS Q3 2025 call?
Will Emergent provide materials or a webcast link for the Q3 2025 results presentation?
